Why this matters
Oxford Biomedica’s decision to turn away an active private equity suitor is an against-trend signal in a market where boards often engage to secure optionality. The message here is pricing discipline, backed by operating momentum, can still force even large sponsors to walk.
The news
Oxford Biomedica has rejected unsolicited takeover proposals from EQT, after the company’s board consulted with key shareholders and concluded the approaches undervalued the business. Following the rejection, EQT confirmed it has no intention to make an offer for Oxford Biomedica.
The process unfolded amid preliminary talks that were extended under UK takeover rules, before Oxford Biomedica ultimately shut the door.
Financial terms were not disclosed.
A board using momentum as leverage
The critical underwriting point is that Oxford Biomedica did not reject on principle. It rejected on price, and it had current trading to support that stance.
The company reported 30% revenue growth in 2025, citing a growing backlog, and it has affirmed a strong growth outlook for FY2026 and beyond. In practical terms, that combination raises the internal hurdle rate for any buyer: if near-term growth is visible and contracted, the board can rationally demand a valuation that pays for it.
EQT’s withdrawal, after pursuing the deal and engaging through extended deadlines, suggests the gap was not a minor one. It also implies the sponsor was unwilling to stretch on entry valuation given today’s financing costs and the sector’s uneven public-market appetite.
What the abandonment signals for healthcare M&A
This episode cuts against the common narrative that sponsors can pressure public-company boards into a process. Here, the board’s unanimous position, supported by key shareholders, held.
Two read-throughs matter for European healthcare dealmaking:
- Valuation expectations remain sticky for quality assets. Companies with visible demand signals (backlog) and strong recent growth can resist opportunistic approaches, even when approached by a credible buyer.
- Public-to-private is not a one-way street. EQT’s unsolicited approach and the use of takeover-rule extensions show private equity remains active in healthcare, but execution depends on aligning around a credible equity story and price.
Integration was never the issue, but conviction was
Because EQT has stepped back, integration planning is hypothetical. Still, the key point for future approaches to Oxford Biomedica, or similar healthcare platforms, is that operational momentum changes negotiating power.
Any renewed bidder would need to answer, in diligence and in price, several questions that boards and shareholders will now be primed to ask:
- How durable is the backlog and what is the conversion profile into revenue and cash?
- What is the customer concentration and renewal risk as the business scales?
- How much incremental investment is required to deliver the FY2026-plus growth outlook?
- What is the credible value-creation plan beyond financial engineering, and what execution bandwidth exists to deliver it?
What to watch next
- Whether Oxford Biomedica’s trading continues to track the FY2026-and-beyond growth narrative.
- Any further inbound interest from sponsors or strategics now that EQT has publicly stepped away.
- Updates on backlog conversion, customer wins, and visibility on forward revenue.
- Shareholder positioning: whether key holders remain aligned behind management’s valuation stance.
- Sector read-through: whether other healthcare targets with strong growth become more resistant to unsolicited bids.